Repligen Corp SEC filings RGEN
Repligen Corp has 1,003 filings in SEC EDGAR's recent list, going back to May 13, 2010. Its latest annual report, Form ARS, was filed on Apr 2, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 30, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (unregistered share sale, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 425 | Filing | Sep 30, 2026 | — |
| 425 | Filing | Sep 8, 2026 | — |
| EFFECT | Filing | Sep 4, 2026 | — |
| 425 | Filing | Aug 4, 2026 | — |
| 425 | Filing | Jul 24, 2026 | — |
| 425 | Filing | Jul 22, 2026 | — |
| 425 | Filing | Jul 22, 2026 | — |
| UPLOAD | Letter from the SEC | Sep 10, 2025 | — |
| CORRESP | Letter to the SEC | Aug 26, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 14, 2025 | — |
| NT 10-K | Filing | Mar 3, 2025 | Dec 31, 2024 |
| NT 10-Q | Filing | Nov 12, 2024 | Sep 30, 2024 |
| UPLOAD | Letter from the SEC | Aug 12, 2024 | — |
| CORRESP | Letter to the SEC | Aug 6, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 24, 2024 | — |
| CT ORDER | Filing | Jan 31, 2022 | — |
| DEFR14A | Filing | May 5, 2021 | — |
| 305B2 | Filing | Jul 15, 2019 | — |
| D | Filing | Jun 13, 2019 | — |
| CT ORDER | Filing | Jun 5, 2018 | — |
| D | Filing | Aug 8, 2017 | — |
| UPLOAD | Letter from the SEC | Mar 8, 2017 | — |
| CORRESP | Letter to the SEC | Feb 14, 2017 | — |
| CORRESP | Letter to the SEC | Jan 24, 2017 | — |
| CORRESP | Letter to the SEC | Jan 9, 2017 | — |
| UPLOAD | Letter from the SEC | Dec 22, 2016 | — |
| CT ORDER | Filing | Jul 26, 2016 | — |
| 305B2 | Filing | May 19, 2016 | — |
| NT 10-K | Form nt 10-k | Mar 3, 2015 | Dec 31, 2014 |
| UPLOAD | Letter from the SEC | Feb 25, 2015 | — |
| CORRESP | Letter to the SEC | Feb 19, 2015 | — |
| UPLOAD | Letter from the SEC | Feb 13, 2015 | — |
| CORRESP | Letter to the SEC | Jan 20, 2015 | — |
| CORRESP | Letter to the SEC | Dec 30, 2014 | — |
| UPLOAD | Letter from the SEC | Dec 23, 2014 | — |
| CT ORDER | Filing | Sep 18, 2014 | — |
| CT ORDER | Filing | Jun 30, 2014 | — |
| D | Filing | Jun 16, 2014 | — |
| CT ORDER | Filing | May 22, 2013 | — |
| CT ORDER | Filing | Jul 26, 2012 | — |
| CT ORDER | Filing | Jul 26, 2012 | — |
| NO ACT | Auto-generated paper document | Apr 17, 2012 | Apr 4, 2012 |
| 8-A12G/A | Form 8-a/a | Sep 8, 2011 | — |
| CT ORDER | Filing | Jul 22, 2010 | — |
| CT ORDER | Filing | Jul 6, 2010 | — |
Showing 45 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- RGEN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 730272
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.